Two Sigma Investments LP Has $15.13 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Two Sigma Investments LP reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 686,455 shares of the company's stock after selling 28,694 shares during the quarter. Two Sigma Investments LP owned 0.06% of Teva Pharmaceutical Industries worth $15,129,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its position in shares of Teva Pharmaceutical Industries by 31.7% during the 3rd quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after acquiring an additional 102,848 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of Teva Pharmaceutical Industries by 23.2% during the 4th quarter. Park Avenue Securities LLC now owns 12,434 shares of the company's stock valued at $274,000 after acquiring an additional 2,341 shares in the last quarter. Diversify Advisory Services LLC boosted its position in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after acquiring an additional 496 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Teva Pharmaceutical Industries by 6.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 1,490,986 shares of the company's stock valued at $32,861,000 after acquiring an additional 90,661 shares in the last quarter. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management boosted its position in shares of Teva Pharmaceutical Industries by 23.9% during the 4th quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 1,716,731 shares of the company's stock valued at $37,837,000 after acquiring an additional 331,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.22 during trading on Wednesday, reaching $17.93. The company had a trading volume of 3,723,076 shares, compared to its average volume of 9,988,086. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market cap of $20.33 billion, a PE ratio of -12.36, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business's 50 day moving average price is $15.43 and its 200-day moving average price is $17.36.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the previous year, the company earned $0.48 EPS. Teva Pharmaceutical Industries's revenue was up 1.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday. They set a "buy" rating and a $25.00 target price for the company. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus target price of $24.50.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.